Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders –– Topline Data Expected Mid-Year 2025 –MELBOURNE, Australia and ...
Alterity Therapeutics (ASX:ATH, NASDAQ:ATHE) has announced the completion of its last patient visit in the ATH434-202 ...
TipRanks on MSN2mon
Alterity Therapeutics announces ATH434 Phase 2 trial resultsAlterity Therapeutics (ATHE) announced topline results from the ATH434-201 randomized, double-blind, placebo-controlled Phase ...
“ATH434 has demonstrated significant slowing of clinical progression and a favourable safety profile in Multiple System Atrophy (MSA), a rare and rapidly progressive disease. We will use funds ...
The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy (MSA). “Following the ...
The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy (MSA). "Following the positive ...
Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback